ORIC will present Phase 1b data for enozertinib (ORIC-114), a selective, brain-penetrant EGFR/HER2 inhibitor, in previously treated HER2 exon 20–mutant NSCLC at ESMO Asia 2025. The study includes a randomized dose-optimization component, signaling a push to finalize a recommended Phase 2 dose. A company webcast is slated for December 6 to discuss the dataset.
The core development is ORIC’s decision to spotlight the HER2 exon 20 cohort from its multi-cohort program, where clinical need is defined by limited small-molecule options and by the practical constraints of ADC therapy in a population with high CNS involvement. With the poster focused on previously treated patients, the readout will be assessed against current real-world sequencing patterns, where many patients now receive an ADC and present with evolving resistance and CNS disease. ESMO Asia is a deliberate venue choice: Asian networks have proven efficient in enrolling genetically defined NSCLC cohorts and in running early dose-refinement designs.
Strategically, this looks like an expansion play into a niche where differentiation is achievable on CNS control and tolerability. The field has seen mixed results with earlier pan-HER TKIs that struggled on rash, diarrhea, and ILD, while ADCs set a high bar on response at the cost of pulmonary toxicity monitoring and infusion logistics. ORIC’s emphasis on selectivity and brain penetration is aimed at two pressure points sponsors are hearing from clinicians and regulators: durable intracranial activity and cleaner safety that supports chronic dosing. Randomizing doses in Phase 1b is an operationally heavier choice, but it can de-risk Phase 2 by quantifying exposure–response and exposure–toxicity trade-offs up front, especially around EGFR/HER2 class effects and ILD surveillance.
For sites and CROs, the implications are concrete. Enrollment hinges on reliable detection of HER2 exon 20 insertions; programs that streamline local testing with centralized confirmation and rapid molecular referrals will outperform. If the dataset includes patients pretreated with ADCs, heterogeneity in prior lines and CNS status will complicate stratification and endpoint interpretation, but it also mirrors current practice. Expect tighter imaging schedules and predefined intracranial endpoints if ORIC aims to claim CNS activity credibly. Safety monitoring frameworks should be calibrated for dermatologic and GI AEs and for ILD signals, given the regulatory sensitivity around pulmonary events in HER2+ lung cancer. For sponsors and payers, dose optimization that preserves response while lowering dose-related toxicity could expand real-world adherence relative to earlier TKIs.
The broader read is that HER2 exon 20 NSCLC is becoming a test case for ADC-to-TKI sequencing and for whether small molecules can reclaim ground by offering oral, CNS-active regimens with manageable toxicity. ORIC-114’s broader target profile across EGFR exon 20 and atypical mutations gives the company latitude, but the HER2 cohort will need to show competitive response and durability in the post-ADC era to justify a dedicated registrational path. Regulators will look for a clean signal on DOR, intracranial responses, and a safety profile that supports continuous dosing without dose erosion.
What to watch next: the headline ORR and DOR, explicit intracranial outcomes, ILD incidence across dose arms, and whether ORIC names an RP2D and signals a single-arm expansion suitable for an accelerated path in ADC-exposed patients. Equally important will be clarity on diagnostic strategy for HER2 exon 20 detection and on geographic scalability of enrollment. The open question is whether enozertinib can differentiate against both ADCs and emerging HER2 TKIs on CNS control and tolerability—requirements that will ultimately dictate regulatory momentum and site adoption.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
